LEGN·Legend Biotech Corporation
LEGN|Analyst Targets
LEGN|Insider Trading
LEGN|Fundamentals
LEGN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.00 | - | - |
| Q3'25 | $-0.18 | $-0.22 | -18.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $369M | - | - |
| Q3'25 | - | $272M | - |
LEGN|Monthly Returns
Market Data
LEGN Stock Snapshot
- Market cap
- 4.41B
- Day range
- $22.23 – $23.64
- News sentiment
- 57/100 · Neutral
- Analyst target
- $45.62 (+93.0%)
- Consensus
- Buy · 24 analysts
The signals on LEGN lean bearish, and the range position backs that up. Thinner liquidity means moves can extend past what the fundamentals alone justify.
Behaviour On Record
What LEGN's own history says about today's numbers
- Realized volatility (21d)
- 54.0% 58th pct
- Below its peak
- -70.1%
- vs 200-day average
- +3.4%
- Up days (1y)
- 43%
Legend Biotech Corporation is currently running 54.0% annualised volatility over the last 21 sessions. Measured against LEGN's own 6 years of daily returns rather than a market-wide average, that is the 58th percentile — close to its own typical level, against a typical reading of 49.6%.
LEGN is trading -70.1% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -43.8%, and the deepest was -53.6% in 2024. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.
Price sits +3.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 62nd percentile — a somewhat wider gap than its own norm. Over the past year LEGN closed higher on 43% of sessions, and it is currently 3 sessions into a rising streak.
On November specifically: over 6 years of records, LEGN finished the month higher 2 of 6 times, with a median return of -3.7% and an average of -1.3%. Its strongest month historically has been June at +15.3% on average, its weakest December at -9.1%.
Overnight risk is measurable too: LEGN has opened more than 2% away from the prior close in 199 of 1,612 sessions (12.3% of the time), with the largest gaps running +7.4% and -6.5%.
All figures computed from 1,613 daily closes between 2020-06-08 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against LEGN's own 6-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of LEGN's sector?
Legend Biotech Corporation sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, LEGN ranks 6th of 15 tracked industries, weakening.
- Sector rank
- #1 of 12
- Sector state
- Weakening
- Sector rotation score
- 100
- Industry rank
- #6 of 15
Analyst Consensus Estimates
What do analysts expect LEGN to earn?
Analysts expect Legend Biotech Corporation to earn -$0.01 per share in the fiscal year ending Dec 2026 and $2.87 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.
Analyst Rating Changes
Are analysts turning bullish or bearish on LEGN?
Barclays most recently reiterated its rating on Legend Biotech Corporation to Overweight on Oct 13, 2026 with a price target of $68 (from $74). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.
- Latest action
- Barclays: Overweight
- 90-day upgrades
- 0
- 90-day downgrades
- 1
- Net rating momentum
- -1
Corporate Stakes
Which companies own a stake in LEGN?
Johnson & Johnson reports a stake in Legend Biotech Corporation on SEC Form 13F: 814.6K shares, about 0.44% of the company, worth $16.2M at the end of Q3 2026. At today's price that stake is worth $19.3M, about 0.00% of JNJ's own market value.
- Holder
- JNJ
- Shares held
- 814.6K
- Stake
- 0.44%
- Value
- $16.2M
Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.
News & sentiment
What is the news saying about LEGN?
LEGN rose 25.2% over the month to Nov 6. News tone held between 0 and 95 from Oct 8 to Oct 20, then jumped to 75 on Oct 27.
- Oct 14 +6.4%
- Oct 16 -6.2%
- Nov 4 +6.1%same day: Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
Technical analysis
How strong is LEGN's momentum right now?
On the daily chart LEGN ranks at the 7th percentile for momentum against 1,060 stocks and ETFs, a bearish reading.
Institutional ownership
Are big funds buying or selling LEGN?
45 of the 85 tracked managers added to LEGN in their latest 13F and 34 trimmed. Together they own 6.0% of the company, worth $318.9M. State Street and Capital International Investors alone hold 1.6%.
- 1State Street Corp0.80%$43.3M positionAdded 0.0% last quarter
- $41.0M positionAdded 119.3% last quarter
- $33.5M positionNew position last quarter
- $21.9M positionAdded 86.8% last quarter
- 5Woodline Partners LP0.35%$19.1M positionAdded 222.1% last quarter
- $16.6M positionTrimmed 0.0% last quarter
- 7UBS Group AG0.27%$14.5M positionAdded 64.6% last quarter
- $9.8M positionTrimmed 61.2% last quarter
- $8.9M positionAdded 297.0K shares last quarter
- $7.3M positionAdded 7.2% last quarter
Discover more
How has LEGN done against its peers?
Over the six months to Nov 6, LEGN returned −18.7%. Of the 15 related stocks and ETFs, 14 did better, led by MRNA at +436.2%.
- 1MRNAModerna, Inc.up 436.2%+454.8 pts
- 2ARKGARK Genomic Revolution ETFup 46.9%+65.6 pts
- 3AMGNAmgen Inc.up 39.3%+57.9 pts
- 4ROIVRoivant Sciences Ltd.up 37.3%+56.0 pts
- 5RPRXRoyalty Pharma plcup 34.6%+53.3 pts
- 6BIIBBiogen Inc.up 30.6%+49.3 pts
- 7RVMDRevolution Medicines, Inc.up 30.0%+48.7 pts
- 8VRTXVertex Pharmaceuticals Incorporatedup 28.1%+46.8 pts
- 15LEGNThis stockdown 18.7%
- 16INSMInsmed Incorporateddown 19.9%−1.2 pts